Post-Traumatic Stress Disorder (PTSD) and Seroquel
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 7/11/2015 |
| Start Date: | February 2010 |
| End Date: | December 2013 |
| Contact: | Evelyne Tschibelu, BS |
| Email: | etschibelu@mclean.harvard.edu |
| Phone: | 617-855-3370 |
Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes
This 8 weeks study will investigate how brain activations in PTSD predict therapeutic
responses to Seroquel pharmacotherapy.
responses to Seroquel pharmacotherapy.
An initial telephone interview will be conducted to determine if potential subjects meet the
basic study requirements. If no obvious counterindications are present, subjects will be
scheduled for a screening visit. After briefing the subjects on the reasons for the
research, they will be given an opportunity to read the Informed Consent Form, approved by
the Cambridge Health Alliance Institutional ReviewBoard, and to ask questions prior to
signing it. Subjects will be given a copy of the signed Consent Form. Each subject will
complete a standardized interview schedule designed to obtain personal and background data
along with psychodiagnostic and psychometric evaluations. An open-label treatment will be
utilized for all patients. Seroquel tablets will be flexibly dosed and begun at a target
dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal
daily dose of 400 mg on subsequent days.
basic study requirements. If no obvious counterindications are present, subjects will be
scheduled for a screening visit. After briefing the subjects on the reasons for the
research, they will be given an opportunity to read the Informed Consent Form, approved by
the Cambridge Health Alliance Institutional ReviewBoard, and to ask questions prior to
signing it. Subjects will be given a copy of the signed Consent Form. Each subject will
complete a standardized interview schedule designed to obtain personal and background data
along with psychodiagnostic and psychometric evaluations. An open-label treatment will be
utilized for all patients. Seroquel tablets will be flexibly dosed and begun at a target
dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal
daily dose of 400 mg on subsequent days.
Inclusion Criteria:
- Provision of written informed consent
- Fluency in English
- A diagnosis of PTSD
- No pregnancy
- Right-handedness
Exclusion Criteria:
- Pregnancy or lactation
- Any cognitive impairment that precludes informed consent
- Known intolerance or lack of response to Seroquel
- Previous enrollment or randomization of treatment in the present study
- Participation in another drug trial within 4 weeks prior enrollment into this study
- Patients with Diabetes Mellitus
- History of allergic reaction or hypersensitivity to Seroquel
- Contraindications to magnetic resonance imaging
- Treatment with an effective medication for PTSD
We found this trial at
2
sites
McLean Hospital McLean Hospital is a comprehensive psychiatric hospital committed to providing easy access to...
Click here to add this to my saved trials
Click here to add this to my saved trials